Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Global Peptide Therapeutics Market to Reach US$46.6 Million by 2024: Increasing Prevalence of Cancer to Create Growth Opportunities, Says TMR


      News provided by

      Transparency Market Research

      26 Apr, 2017, 14:30 GMT

      Share this article

      Share this article


      ALBANY, New York, April 26, 2017 /PRNewswire/ --

      According to a new research report by Transparency Market Research (TMR), market players with large revenue base, such as Sanofi, Eli Lilly, Novo Nordisk, and Teva, have been dominating the global peptide therapeutics market. In 2015, these companies together held a share of more than 75% in this market.

      These market players are conducting rigorous research and have taken up various development initiatives to accentuate their respective market shares, which is likely to increase the competition within this market, reports the research study.

      As per TMR's estimations, the opportunity in the worldwide market for peptide therapeutics was worth US$21.3 bn in 2015. The market is expected to expand at a CAGR of 9.10% during the period from 2016 and 2024 and reach US$46.6 mn by the end of the forecast period. The demand for peptide therapeutics is significantly high for the treatment of cancer. Researchers at TMR expect the trend to remain so over the next few years.

      Browse Market Research Report @ http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

      Immunopeptides to Report Significant Growth 

      The report analyzes the global market for peptide therapeutics on the basis of a number of market parameters. One among them is the type of molecule, based on which, the market has been classified into vasopressin, somatostatin, calcitonin, natriuretic, and immunopeptide. Thanks to the increasing usage of immunopeptide for the treatment of several conditions, such as cancer and tumors, the immunopeptide segment has been registering a higher growth than others.

      Since the treatment of these diseases is complex, more investments is being made by the key market players in research and development of various therapies, amongst which the immuno therapy is the most favored one. This, as a result is anticipated to reflect positively on the growth of the immunopeptide segment in the near future, notes the study.

      In terms of the geography, the report segments the worldwide market for peptide therapeutics into the Middle East and Africa, Latin America, North America, Europe, and Asia Pacific. In 2015, North America acquired the leading position in the global market with a share of 38.8%. Researchers expect this regional market to retain its position over the period of the forecast, thanks to the infrastructural advancements in the medical and healthcare industry. The emergence of peptide therapeutics as a highly potent drugs for the treatment of cancer and various other diseases and the presence of large pool of leading players in the U.S. are also projected to boost the North America market for peptide therapeutics in the years to come.

      Get an exclusive sample of the report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418

      Increasing Usage of Peptides in Cancer Treatment to Boost Market's Growth 

      "The rising prevalence of cancer is the key factor behind the significant growth of the global peptide therapeutics market," states a TMR analyst. According to the WHO, nearly 7 million people die from cancer every year and there will be more than 16 million new cancer cases every year by 2020. Since chemotherapy is facing major challenges due to its inability to deliver the correct amount of drug directly, the application of peptides in cancer treatment has increased, opening new avenues for future growth.

      Going forward, the rising incidence rate of metabolic disorders is likely to create lucrative opportunities for market players in the years to come. However, the lack of regulatory standards may restrict the market from growing steading over the next few years, states the research report.

      The study presented here is based on a report by Transparency Market Research (TMR), titled "Peptide Therapeutics Market (Application - Cancer, Metabolic, CVD, Respiratory, GIT, Anti-infective, Dermatology, CNS, and Renal; Route of Administration - Parenteral and Oral; Type - Innovative and Generic; Technology - Liquid Phase, Solid Phase, and Hybrid Phase; Type of Molecule - Vasopressin, Somatostatin, Calcitonin, and Natriuretic, Immunopeptide; API Peptide Type - In-house and CMO) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024."

      The global Peptide Therapeutics Market has been segmented into:

      By Application 

      • Cancer
      • Metabolic
      • CVD
      • Respiratory
      • GIT
      • Anti-infective
      • Dermatology
      • CNS
      • Renal
      • Others

      By Route of Administration 

      • Parenteral
      • Oral
      • Others

      By Type 

      • Innovative
      • Generic

      By Technology 

      • Liquid Phase
      • Solid Phase
      • Hybrid Phase

      By Type of Molecule 

      • Vasopressin
      • Somatostatin
      • Calcitonin
      • Immunopeptide
      • Natriuretic
      • Others

      By API Peptide Type 

      • In-house
      • CMO

      By Geography 

      • North America
        • U.S.
        • Canada
      • Europe
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Rest of Europe
      • Asia Pacific (APAC)
        • Japan
        • China
        • India
        • Rest of APAC
      • Latin America (LATAM)
        • Brazil
        • Mexico
        • Rest of LATAM
      • Middle East & Africa (MEA)
        • South Africa
        • Saudi Arabia
        • Rest of MEA

      Browse Related Research Report: 

      Collagen Peptide and Gelatin Market (Type - Type I (Fish and Others), and Type II (Hydrolyzed and Undenatured)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2025

      http://www.transparencymarketresearch.com/collagen-peptide.html

      Non-Small Cell Lung Cancer Therapeutics Market (Pipeline - Early Stage (Phase I and II) and Late Stage (Phase III); Drug Class - Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

      http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

      Cancer Therapeutics and Biotherapeutics Market - Global Industry Size, Share, Trends, Analysis and Forecasts 2016 - 2024

      http://www.transparencymarketresearch.com/cancer-therapeutics-and-biotherapeutics-market.html

      About Us: 

      Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

      Contact Us:

      Transparency Market Research
      90 State Street, Suite 700
      Albany, NY 12207
      Tel: +1-518-618-1030
      USA - Canada Toll Free: 866-552-3453
      Email: sales@transparencymarketresearch.com


      Website: http://www.transparencymarketresearch.com
      Blog: http://www.tmrblog.com/


      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.